KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Invested Capital (2016 - 2026)

Supernus Pharmaceuticals has reported Invested Capital over the past 15 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly Invested Capital rose 0.89% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 0.89% year-over-year, with the annual reading at $1.1 billion for FY2025, 0.89% up from the prior year.
  • Invested Capital was $1.1 billion for Q4 2025 at Supernus Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $1.3 billion in Q3 2022 and troughed at $786.0 million in Q1 2021.
  • The 5-year median for Invested Capital is $992.7 million (2024), against an average of $1.0 billion.
  • Year-over-year, Invested Capital soared 54.06% in 2021 and then dropped 24.29% in 2023.
  • A 5-year view of Invested Capital shows it stood at $1.2 billion in 2021, then fell by 24.08% to $907.3 million in 2022, then grew by 7.3% to $973.6 million in 2023, then increased by 11.25% to $1.1 billion in 2024, then increased by 0.89% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Invested Capital are $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.1 billion (Q2 2025).